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1. Introduction 
Hodgkin lymphoma (HL) is an uncommon lymphoid malignancy which accounts for about 
0.5% to 1% of all cancers. In 2010, an estimated 8,490 new cases and 1,320 deaths will occur 
in the United States (Jemal, Siegel, Xu, et al, 2010). HL incidence appears to be stable over the 
past few decades, in contrast to the incompletely understood continued increase in 
frequency of non-Hodgkin lymphomas. HL has a bimodal incidence with most patients 
diagnosed in the third decade, followed by another peak in adults aged 55 years or older. 
There has been correlation between incidence of certain histologic sybtypes of HL and age 
and sex; for example, nodular-sclerosis HL is more common  in women and young adults in 
contrast to mixed cellularity HL which is more common in men and lymphocyte-rich HL 
which is more common in older males (Correa, O'Conor, Berard, et al, 1973).  
The cause of HL remains unknown, but there has been some progress in identifying risk 
factors in development of HL. Factors associated with HL include genetic predisposition 
(increased incidence in certain ethnic populations such as Jews and in first degree relatives 
such as siblings, twins and children), viral exposures, and immune suppression (Bernard, 
Cartwright, Darwin, et al, 1987; Glaser & Jarrett, 1996; Lynch, Marcus & Lynch, 1992; Mack, 
Cozen, Shibata, et al, 1995). Epstein-Bar virus (EBV) has been implicated in the etiology of 
HL based on epidemiological and serologic studies (Weiss, Strickler, Warnke, et al, 1987), as 
well as by the detection of the EBV genome in tumor specimens of about half of HL nodes. 
Moreover, HIV-infected patients have been noted in many studies to have a significantly 
increased risk of HL with the majority of patients presenting with advanced stages, having 
extranodal involvement and unfavorable histological subtypes, and associated with a poorer 
outcome after initial therapy (Levy, Colonna, Tourani, et al, 1995; Tirelli, Errante, Dolcetti, et 
al, 1995). 
The past few decades have seen major advances in treatment of HL using both, radiation 
therapy (RT) and chemotherapy. With advances in combination chemotherapy regimens and 
RT techniques over the past four-five decades, HL has changed from an incurable disease to 
one with the best survival rates to date among other cancers. HL is currently curable in 85% to 
95% of cases, depending on disease stage at time of diagnosis and other risk factors (Diehl, 
2007). In the H8-F trial, Ferme’ et al. reported a 10-year overall survival (OS) estimates of 97% 
in early-stage disease (Ferme, Eghbali, Meerwaldt, et al, 2007). In fact, cure rates for HL have 
increased so extensively that the overriding treatment considerations often relate to long-term 
toxicity, especially for patients with early- or intermediate-stage disease (Hoppe, Advani, Ai, et 
al, 2011). For advanced disease, clinical trials still emphasize improvement in cure rates, but 
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the potential long-term effect of treatments remain an important consideration as well. New 
innovative treatment strategies are clearly needed for the refractory and recurrent disease, as 
the cure rates in these patients are still low, especially for those who relapse after autologous 
stem cell transplantation (ASCT). 
In this chapter, we will discuss briefly the initial workup and staging at the time of 
diagnosis with brief review of the role of positron emission tomography (PET) scan in HL. 
We will then go through the revised response criteria, followed by a thorough review for the 
management of early stage HL including the various definitions of the favorable and 
unfavorable risk groups as determined by major study groups. Management of HL in 
specific populations such as the NLPHL, elderly, and pregnant patients will be reviewed in 
this chapter as well.  
2. Diagnosis/staging 
Hodgkin lymphomas are defined as lymphomas containing one of the characteristic types of 
Reed-Stenberg (RS) cells in a background of nonneoplastic cells. Based on the morphology 
and immunophenotype of the RS cells and the composition of the cellular background, the 
WHO classification system published in 2001 divided HL into two disease entities: classical 
HL (cHL) which accounts for 95% and nodular lymphocyte-predominant HL (NLPHL) 
which accounts for 5% of all HL cases. cHL is further divided into 4 subtypes: nodular 
sclerosis (grades I or II), mixed cellularity, lymphocyte depleted, and lymphocyte-rich cHL 
(Diehl V, 2005b; Harris, Jaffe, Diebold, et al, 1999; Jaffe ES, 2001). cHL and NLPHL share the 
same diagnostic workup, though they have different natural history and distinctive 
morphologic and immunophenotypic features (Table 1), and ultimately different approach 
of therapy. 
 
  Classic HL NLPHL 
Pattern Diffuse, interfollicular, nodular Nodular, at least in part 
Tumor cells Diagnostic RS cells; mononuclear or lacunar cells L&H or popcorn cells 
Background Lymphocytes (T cells > B cells), histiocytes, 
eosinophils, plasma cells 
Lymphocytes (B cells > 
T cells), histiocytes 
Fibrosis Common Rare 
CD15, CD30 + – 
CD45 & CD57 + 
T cells 
– + 
EMA – + 
CD20 ± + 
EBV (in RS cells) + (~50%) – 
Nuclear bcl-6 
protein 
– + 
Ig genes (single-
cell PCR) 
Rearranged, clonal, mutated, "crippled" 
Rearranged, clonal, 
mutated, ongoing 
EBV, Epstein-Barr virus; EMA, epithelial membrane antigen; Ig, immunoglobulin; L&H, lymphocytes 
and histiocytes; PCR, polymerase chain reaction; RS, Reed-Sternberg. 
Adapted from De Vita et al. Cancer. Principles & practice of oncology. Philadelphia: Lippincott 
Williams and Wilkins; 2005. 
Table 1. Morphologic and Immunophenotypic Features of cHL Compared to NLPHL. 
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Diagnosis of HL should always be established by a tissue biopsy; though a core needle 
biopsy may be adequate, an excisional lymph node biopsy is preferred and highly 
recommended. FNA alone is generally insufficient for the evaluation of architecture and for 
immunophenotyping, and should be avoided (Caraway, 2005; Hehn, Grogan & Miller, 2004; 
Meda, Buss, Woodruff, et al, 2000). Rarely, multiple LN biopsies may be necessary for the 
diagnosis, as the cytokines associated with HL can produce reactive hyperplastic changes in 
adjacent lymph nodes (Ansell & Armitage, 2006).  
Though it might not be necessary for typical cases of cHL, immunohistochemistry staining is 
recommended for accurate diagnosis of any case of HL with atypical features and many cases 
of NLPHL. cHL is usually positive for CD15 and CD30, but negative for CD3 and CD45. 
NLPHL usually stains positive for CD45 and CD20, but negative for CD15, and rarely 
expresses CD30 (Hoppe, Advani, Ai, et al, 2011)(Table 1). Also, in contrast to NLPHL, the RS 
cells of cHL lack the nuclear bcl-6 protein associated with follicle center B cells (Falini B, 1995). 
Staging of HL is based on the Ann Arbor staging system that was developed in 1971 
(Carbone, Kaplan, Musshoff, et al, 1971) and further modified in 1989 through a consensus 
meeting held in Cotswolds, England (Lister, Crowther, Sutcliffe, et al, 1989) (Table 2). 
 
Stage Definition/Disease Involvement 
I Involvement of a single lymph node region (I) or a single extralymphatic site (IE).  
II Involvement of two or more lymph node regions on the same side of the diaphragm 
(II) or localized involvement of only one extranodal organ or site and of ≥1 lymph 
node regions on the same side of the diaphragm (IIE).  
III Involvement of lymph node regions on both sides of the diaphragm (III), which may 
also be accompanied by involvement of the spleen (IIIS) or by localized involvement 
of an extranodal organ or site (IIIE) or both (IIIS + E).  
IV Diffuse involvement of one or more extranodal organs or sites, with or without 
associated lymph node involvement.  
Each Stage may be subdivided into: 
A No symptoms. 
B General symptoms include any of the following: fever (unexplained temperatures 
>38°C over the preceding one month), drenching night sweats, unexplained loss of 
>10% body weight within the preceding 6 months.  
X Bulky disease which is defined by any nodal mass with a maximal dimension ≥10 cm 
or a mediastinal mass exceeding one third of the widest transverse transthoracic 
diameter measured on a standard PA chest radiography.  
E Involvement of a single extranodal site that is contiguous or proximal to the known 
nodal site.  
Table 2. Modified Ann Arbor Staging System for HL. 
Initial staging evaluation starts with a detailed history and physical examination. History 
should focus on the presence or absence of systemic B symptoms (unexplained fevers >38 °C 
within the preceding month, drenching night sweats, and unexplained weight loss of >10% 
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body weight within the preceding 6 months), performance status, pruritus, alcohol intolerance, 
and any history of prior cancers and treatments received (chemotherapy and/or RT). Of 
notice, cHL compared to NLPHL, presents more commonly with B symptoms (about one third 
of patients with HL), pruritus, alcohol-induced pain, and extra nodal disease involvement. 
Physical examination should be focused on all lymphoid regions in addition to the liver and 
spleen.  
The National Comprehensive Cancer Network (NCCN) established certain laboratory and 
radiographic studies which are recommended at the initial evaluation of patients with HL. 
These include (NCCN, v.2.2011) CBC with differential and platelets, ESR, LDH, albumin, 
liver and kidney function tests, and a pregnancy test for women of childbearing age. An 
adequate bone marrow (BM) biopsy should be performed for stages IB-IIB and stages III-IV 
disease. More invasive procedures such as liver biopsy, diagnostic laparotomy, or 
splenectomy are restricted to a very small subgroup of patients where initial staging is 
inconclusive. Radiographic studies should include at least chest x-ray and diagnostic 
computed tomography (CT) of the chest, abdomen and pelvis. CT-PET scan has become an 
integral part of initial staging as well. Neck CT is recommended if RT is planned. 
2.1 Role of PET in HL 
The role of PET in HL has been markedly evolving over the past few years. It has been used 
and shown to have high positivity and specificity for initial staging and restaging in patients 
with lymphoma (Isasi, Lu & Blaufox, 2005; Seam, Juweid & Cheson, 2007). In a review done 
by Juweid ME (Juweid, 2006a), the use of PET scan in HL results in a modification of disease 
stage (usually upstaging) in about 15-20% of patients with an impact on management in 
about 5-15%. However, it remains unclear whether patients would benefit from a 
subsequent change in the treatment plan, and therefore, the value of PET for initial staging 
of HL patients outside a clinical trial is still debatable. On the other hand, as reviewed by 
Juweid, response assessment after completion of therapy is currently the most widely 
utilized application of restaging PET in HL and can be considered the standard of care for 
post treatment assessment of patients with HL. In this setting, PET shows an excellent 
negative predictive value between 91 and 95% in several studies, but the positive predictive 
value is substantially lower and considerably more variable averaging approximately 65% 
(de Wit, Bohuslavizki, Buchert, et al, 2001; Juweid, 2006a; Weihrauch, Re, Scheidhauer, et al, 
2001). To decrease the false positive results, the International Harmonization Project (IHP), 
recommends that PET not be performed for at least 3 weeks following chemotherapy and 
preferably 8-12 weeks after completion of radiotherapy (Juweid, 2006b). The role of PET 
scan for routine post therapy surveillance remains controversial, primarily because of the 
potential for a disproportionate fraction of false-positive findings, potentially resulting in 
increasing cost without proven benefit from earlier PET detection of disease compared to 
standard surveillance methods (Cheson, Pfistner, Juweid, et al, 2007; Jerusalem, Beguin, 
Fassotte, et al, 2003). 
Another evolving and interesting use of PET scan is in the assessment of early response; 
interim PET scan findings has been significantly correlated with treatment outcomes in 
terms of progression-free survival (PFS) and OS. Recently, PET scanning was proposed to 
assist in determining the choice of therapy. Patients with negative PET scans after 2-3 cycles of 
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treatment are being considered for an abbreviated course of chemotherapy alone, whereas 
those with positive PET scan are treated in a more standard fashion with the combined 
modality. The ongoing United Kingdom (RAPID trial) is testing whether PET scanning can 
guide therapy in early HL after 3 cycles of chemotherapy; PET-negative patients are 
randomized to involved field RT (IF-RT) versus observation while PET-positive are treated 
with 4th cycle ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by IFRT. The 
recently initiated EORTC/GELA H10 Intergroup trial is comparing ‘standard therapy’ to PET-
based response-adapted therapy (i.e. PET after 2 cycles ABVD) for favorable and intermediate 
group patients with early-stage HL. 
3. Response criteria 
Uniform and standardized criteria for assessment of initial treatment response are essential 
since they guide for additional treatment and are required for interpreting and comparing 
clinical trials. Hence, the International Working Group (IWG) published guidelines for non-
Hodgkin’s lymphoma response criteria first time in 1999 (Cheson, Horning, Coiffier, et al, 
1999; Cheson, Pfistner, Juweid, et al, 2007). The HL study groups have adopted these IWG 
criteria which were based on the size reduction of the enlarged lymph nodes (as measured 
with CT scan) and the extent of BM involvement; bone marrow aspirate and biopsy should 
only be performed to confirm a CR if they were initially positive or if it is clinically indicated 
by new abnormalities in the peripheral blood counts or blood smear. 
The IWG guidelines were revised in 2007, by the IHP, after incorporating the PET scans, 
immunohistochemistry, and flow cytometry in the definitions of response for both NHL and 
HL (Table 3). Using the revised system, response is simplified to complete response (CR), 
partial response (PR), stable disease (SD), relapsed disease, or progressive disease (PD) (see 
table 3). CRU (complete response uncertain) category was eliminated from the new 
guidelines, based on the improved ability of PET scans to distinguish between viable tumor 
and necrosis or fibrosis in residual masses present after treatment (Buchmann, Reinhardt, 
Elsner, et al, 2001; Jerusalem, Beguin, Fassotte, et al, 1999; Jerusalem, Warland, Najjar, et al, 
1999; Wirth, Seymour, Hicks, et al, 2002).  
More recently integrated PET/CT scan, which combines a PET and a CT scan in a single 
study, has been shown to provide at least equal information to that obtained separately by 
PET and CT scans. This is supported mostly by retrospective and small trials (Juweid, 
2006a). The recent increase in use of combined PET/CT scans may further help in distinction 
between viable and nonviable tumors. 
4. Treatment 
4.1 Background 
Traditionally, treatment modality for HL had been chosen based on clinical stage. Early-
stage HL includes the limited stages I, II, and IIIA  whereas advanced HL includes stage IIIB 
and stage IV, according to the Cotswolds modification of the Ann Arbor classification 
(Josting, Wolf & Diehl, 2000). Major advances in treatment modalities over past 3 decades 
made early stage HL highly curable with rates achieving up 97% after 10-year follow up as 
reported by Ferme et al (Ferme, Eghbali, Meerwaldt, et al, 2007). Such high cure rates for  
www.intechopen.com
       
 
T
ab
le 3. R
ev
ised
 R
esp
o
n
se C
riteria/
D
efin
itio
n
s fo
r L
y
m
p
h
o
m
a. 
Abbreviations: CR, complete remission; FDG, [18F]fluorodeoxyglucose; PET, positron emission tomography; 
partial remission; SPD, sum of the product of the diameters; SD, stable disease; PD, progressive disease. Sour
Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J of Clin Oncol 2007;25(5):579-
w
w
w
.intechopen.com
 
Treatment of Early Stage Hodgkin Lymphoma 
 
119 
early stage HL made the focus of recent studies on minimizing acute and late therapy related 
toxicities without decreasing the excellent treatment outcomes. Hence, there have been various 
attempts to modify different treatment modalities such as omitting RT, decreasing the dose 
and/or field of RT, and modifying the chemotherapy. In order to maintain efficacy and 
decrease toxicity, clinical investigators, through major randomized studies, were able to 
identify adverse prognostic factors that may predict treatment outcomes in different groups of 
patients. We will discuss and define below these risk groups according to published data from 
major study groups in Europe and North America. Subsequently, we will discuss the 
management of early stage HL according to different risk groups. 
4.2 Definitions of favorable and unfavorable early-stage HL 
In addition to the clinical stage and B symptoms which have traditionally known to be of 
prognostic value, various other adverse factors have been identified based on large cohorts 
over several years. As there have been different approaches to treat HL among major study 
groups which ultimately lead to different prognostic variables, various definitions for 
different risk groups do exist among these cooperative research groups. 
In Europe, three different risk groups are defined: early-stage favorable, early-stage 
unfavorable (intermediate) and advanced-stage HL (Table 4). The NCCN  divides HL into 3 
groups: early-stage favorable (stage I-II with no B symptoms or large mediastinal 
adenopathy), early-stage unfavorable (stage I-II with large mediastinal mass, with or 
without B symptoms; stage I-II with B symptoms; numerous sites of disease; or significantly 
elevated ESR), and advanced-stage disease (stage III-IV). However, some centers in 
Northern America define only two risk groups, namely limited-stage (IA and IIA without 
bulky disease) and advanced-stage HL [III and IV; B symptoms; bulky disease (≥10 cm)] 
(Fuchs, Diehl & Re, 2006). 
NCCN unfavorable risk factors for stage I-II disease include bulky mediastinal disease 
(mediastinal mass ratio >0.33) or bulky disease >10 cm, B symptoms, ESR >50 and more 
than 3 nodal sites of disease. NCCN further classifies unfavorable stage I-II disease into 
stage I-II (unfavorable with bulky disease) and unfvaorable stage I-II with bulky disease and 
unfvaorable stage I-II with non-bulky disease. The European Organization for Research and 
Treatment of Cancers (EORTC) definitions of favorable and unfavorable early stage HL are 
very similar to those for early stage HL in the German HL Study Group (GHSG) (Table 4) 
(Carde, Burgers, Henry-Amar, et al, 1988; Loeffler, Pfreundschuh, Ruhl, et al, 1989; Mauch, 
Tarbell, Weinstein, et al, 1988; Tubiana, Henry-Amar, Carde, et al, 1989). The EORTC criteria 
differs by substituting age ≥50 years in place of the extra nodal disease criterion and 
specifying ≥4 involved regions rather than ≥3, as in GHSG (Noordijk, Carde, Dupouy, et al, 
2006). Moreover, the National Cancer Institute of Canada (NCIC) and the Eastern 
Cooperative Oncology Group (ECOG) subdivided early-stage HL into risk categories, with 
‘low risk’ being NLPHL and nodular sclerosis histology, age <40 years, erythrocyte 
sedimentation rate (ESR) <50, and ≤3 disease regions. ‘High risk’ group patients were all 
other cases with stage I-II disease, except those with bulky disease > 10 cm, which are 
assigned to advanced-stage disease (Table 4) (Evens, Hutchings & Diehl, 2008; Meyer, 
Gospodarowicz, Connors, et al, 2005). 
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 GHSG EORTC/GELA NCIC/ECOG NCCN 
Risk Factors 
(RF) 
A 
Large 
mediastinal 
mass 
A 
Large 
mediastinal 
mass 
A 
Bulky disease 
>10 cm 
A 
Large 
mediastinal 
mass (MMR 
>0.33) or 
bulky disease 
(>10 cm) 
 B 
Extranodal 
disease 
B Age ≥50 y B Age ≥40 B ESR ≥50, if 
asymptomatic 
 C 
ESR ≥50 or B 
symptomsa 
with ESR ≥30 
C 
Same as for 
GHSG1 
C 
ESR ≥50 or 
any B 
symptoma 
C B symptomsa 
 D 
≥3 involved 
nodal regions 
D 
≥4 involved 
nodal regions 
D 
>3 involved 
nodal regions 
D 
>3 involved 
nodal regions 
   E 
MCHL or 
LDHL 
  
Treatment 
groups 
    
Lymphocyte 
predominant 
NLPHL histology 
in CS I–II with no 
RF 
NLPHL histology in 
supradiaphragmatic 
CS I–II 
Low 
risk 
early 
stage 
CS I–II 
with no 
RF 
 
Early stage 
favorable 
CS I–II with no RF 
CS I–II 
supradiaphragmatic 
with no RF 
CS I-II with none 
of the RFs 
Early stage 
unfavorable 
CS I, CS IIA with 
any RF; CS IIB 
with C/D but 
without A/B 
CS I–II 
supradiaphragmatic 
with any RF 
High 
risk 
early 
stage 
CS I-II 
with 
any RF 
except A 
CS I-II with any 
of the RFs 
Advanced 
stage 
CS IIB with A/B; 
CS III–IV 
CS III–IV 
CS I–II with A; 
CS III–IV 
CS III-IV 
Abbreviations: CS, clinical stage; EORTC, European Organization for Research and Treatment of 
Cancer; ESR, erythrocyte sedimentation rate; GELA, Groupe d'Etude des Lymphomes de l'Adulte; 
GHSG, German Hodgkin Study Group; LDHL, lymphocyte depleted HL; MCHL, mixed cellularity HL; 
MMR, mediastinal mass ratio, maximum width of mass/maximum intrathoracic diameter; 
NCIC/ECOG, National Cancer Institute of Canada/ Eastern Cooperative Oncology Group; NCCN, 
National Comprehensive Cancer Network; NLPHL, nodular lymphocyte-predominant Hodgkin's 
lymphoma; RF, risk factor 
aB symptoms include fever with temperature >38oC, drenching night sweats, and unexplained weight 
loss of >10% body weight within 6 months. 
 bSource: Derived from Table 21.2 by Srour S.A. and Fayad L.E. (Srour & Fayad, 2010).  
Table 4. Unfavorable Factors and Treatment Groups According to Major Study Groups and 
NCCN. 
4.3 Treatment of early stage cHL 
Treatment of HL is becoming more standardized in the current era of rapidly evolving 
medical literature and with the marked advances in high technique imaging studies. The 
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most accepted standard of care to date is the combined modality treatment (CMT) with 
chemotherapy and radiotherapy (Table 5). However, there has been some controversy 
about the best RT field/dose and/or the best chemotherapy regimens. We will discuss 
below some of these issues. 
Histology Prognostic Group Recommended Treatment 
Early Stage cHL Favorablea 
Chemotherapyb, d + 20 Gy to 30 Gy IF-RT (most 
commonly accepted protocol) 
or 
Chemotherapy alone with 4-6 cycles of ABVD 
(category 2Be per NCCN Guidelines) 
 Unfavorablea Chemotherapyc, d+ 30 Gy to 36 Gy IF-RT 
Early Stage 
NLPHL 
CS IA 
Local LN excision (limited data) or IF-RT alone 
(preferred option) 
CS IIA 
Regional RT or IF-RT alonef (preferred option  by most 
investigators) 
 CS IB–IIB Chemotherapyg followed by IF-RT 
aSee Table 4 for the definitions of favorable and unfavorable prognostic groups 
bFor favorable early stage cHL, the most commonly used regimens are the ABVD (2 to 4 cycles) and the 
Stanford V regimen (2 cycles) 
 cFor unfavorable early stage cHL, either ABVD is given for 4 to 6 cycles or Stanford V for 3 cycles 
dSee Table x for the chemotherapy regimen abbreviations and dosages 
eCategory 2B, per NCCN, is defined as follows: the recommendation is based on lower-level evidence 
and there is nonuniform NCCN consensus (but no major disagreement) 
fIn the setting of non-bulky CS IIA NLPHL 
gGiven the rarity of NLPHL, no large randomized trials regarding the best chemotherapeutic regimen 
are done. ABVD is widely used based on data for cHL. Immunotherapy with rituximab has been shown 
recently to have excellent response rates in NLPHL. See text for further details. 
CS, clinical stage; IF-RT, involved field radiation therapy; NCCN, National Comprehensive Cancer 
network; RT, radiation therapy 
Table 5. Recommended Treatments for Early Stage HL Commonly Adopted in Europe and 
USA. 
4.3.1 Radiotherapy alone 
It was first noticed in 1950, by Peters (Peters, 1950), that aggressive RT might cure patients 
with limited stage HL. It was not then until early 1960’s when extended field RT (EF-RT) 
was adopted as standard of care for early stage HL. However, EF-RT was complicated by 
high relapse rates (Horwich, Specht & Ashley, 1997) and serious long-term side effects 
including pulmonary dysfunction, heart disease and secondary cancers (Gustavsson, 
Osterman & Cavallin-Stahl, 2003). Hence, in an attempt to lessen toxicity and improve 
treatment outcomes, several studies over the past 3 decades addressed those concerns 
through modifying the radiation field/dose and/or incorporating chemotherapy to RT. 
Multiple randomized studies revealed that combined modality treatment (RT plus 
chemotherapy) has superior outcomes and less toxicity to RT alone. Of importance are the 
two randomized studies by Press et al (Press, LeBlanc, Lichter, et al, 2001) and Engert et al 
(Engert, Franklin, Eich, et al, 2007) which compared RT alone in early stage favorable HL to 
combined modality with chemotherapy followed by RT. Press el al compared 3 cycles of 
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chemotherapy (doxorubicin + vinblastine) followed by subtotal lymphoid irradiation (STLI) 
to STLI alone with freedom from treatment failure (FFTF) of 94% vs. 81% after 3 years of 
follow up in favor to combined modality arm. Engert et al compared EF-RT alone to 
combined modality with 2 cycles of ABVD followed by EF-RT. Superior outcomes were in 
favor to the combined therapy after 7 years of follow up with FFTF of 88% vs. 67%.  
Therefore, treatment with large radiation fields alone has been abandoned and the 
availability of less toxic and more effective chemotherapy made the combined modality 
therapy the standard of care in treating early HL over the past 10-15 years. The only 
exception is those patients with stage IA NLPHL who might benefit from RT alone as will be 
discussed below. 
4.3.2 Early stage favorable cHL 
Almost all investigators in Europe and US now agree that patients with favorable early 
stages HL should receive combined modality therapy. However, there is still no consensus 
as to what chemotherapy should be used, how many cycles should be delivered, and how 
much RT should be administered, if at all. The application of chemotherapy prior to 
irradiation not only led to better treatment results but also enabled the reduction of EF-RT to 
IF-RT in this group of patients (Bonadonna, Bonfante, Viviani, et al, 2004; Diehl V, 2005a; 
Hagenbeek A, 2000; Noordijk EM, 2005) and also lead to a meaningful reduction (up to 50%) 
in the effective prescribed radiation dose (Yahalom, 2006). 
Among other regimens (chemotherapy regimens abbreviations are listed in Tables 6-8), 
ABVD and Stanford V have been favored as frontline regimens in the combined modality 
with RT in the early stage HL (see Table 6 for regimen details and dosages). ABVD was first 
introduced by Bonadonna et al in 1975 for patients who failed MOPP with very promising 
results. Hence, Santoro and colleagues (Santoro, Bonadonna, Valagussa, et al, 1987) 
compared then three cycles of MOPP vs. ABVD as frontline therapy followed by EF-RT and 
three additional chemotherapy cycles in an attempt to improve outcomes and decrease 
toxicities associated with MOPP. ABVD arm had superior outcomes with better freedom 
from progression (FFP) rates (81% vs. 63%) and lower rates of sterility and leukemia. Since 
then, many studies were conducted by major study groups in Europe and USA and 
compared the combination of either EF-RT or IF-RT with different chemotherapy regimens 
like ABVD, MOPP, MOPP/ABV, EBVP, COPP and BEACOPP, among others. Table 7 
summarizes some of the major studies addressed the combined modality treatment with the 
treatment outcomes. 
The Stanford V regimen, which incorporated the active agents from ABVD and MOPP into a 
brief dose-intense regimen, is one of the relatively new regimens that also has been proven, 
combined with radiotherapy, to be highly effective in early stage favorable and unfavorable 
or locally extensive HL with low toxicity profile.  
The number of chemotherapy cycles (2 to 4 ABVD versus 2 to 3 Stanford V), and the 
intensity of radiation, have been addressed by multiple randomized studies to date with 
major impact on current therapy guidelines. Bonadonna et al (Bonadonna, Bonfante, Viviani, 
et al, 2004) revealed a noninferiority outcomes with 4 cycles of ABVD followed by IF-RT 
compared to same chemotherapy followed by EF-RT after 12 years of follow up (FFP rates of 
93% for ABVD followed by EF-RT vs. 94% for ABVD followed by IF-RT). Horning S 
(Horning SJ, 2004), in a single arm study, showed as well that the 8-week modified 
Stanford V chemotherapy (rather than the standard 12 –week cycle) followed by IF-RT has  
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Regimen Dosage and schedule Frequencya 
ABVDb 
Doxorubicin 25 mg/m2 IV on days 1 and 15 
Bleomycin 10 units/m2 IV on days 1 and 15 Repeat cycle every 28 days 
Vinblastine 6 mg/m2 IV on days 1 and 15  
Dacarbazineb 375 mg/m2 IV on days 1-5  
Standard BEACOPPc   
Bleomycin 10 units/m2 IV on day 8  
Etoposide 100 mg/m2 IV on days 1, 2, and 3  
Doxorubicin 25 mg/m2 IV on day 1 Repeat cycle every 21 days 
Cyclophosphamide 650  mg/m2 IV on day 1  
Vincristined 1.4 mg/m2 IV on day 8 
 Procarbazine 100 mg/m2 PO on days 1-7 
Prednisone 40 mg/m2 PO on days 1-14 
Esc-BEACOPPc 
Bleomycin 10 mg/m2 IV on day 8 Repeat cycle every 21 days 
Etoposide 200 mg/m2 IV on days 1, 2, and 3  
Doxorubicin 35 mg/m2 IV on day 1 
 
Cyclophosphamide 1200 mg/m2 IV on day 1 
Vincristined 1.4 mg/m2 IV on day 8 
Procarbazine 100 mg/m2 PO on days 1-7 
Prednisone 40 mg/m2 PO on days 1-14 
Filgrastime 300 mcg/day starting on day 8 
STANFORD Vf 
Doxorubicin 25 mg/m2 IV on days 1 and 15 
Repeat cycle every 28 days 
Vinblastineg 6 mg/m2 IV on days 1 and 15 
Mechlorethamine 6 mg/m2 IV on day 1 
Vincristineg 1.4 mg/m2 IV on days 8 and 22 
Bleomycin 5 units/m2 IV on days 8 and 22 
Etoposide 60 mg/m2 IV on days 15 and 16 
Prednisoneh 40 mg/m2 PO every other day 
aThe duration of chemotherapy and number of cycles are determined by the stage of the disease and the 
prognostic stratification (see text for details) 
bABVD regimen was used first as described in the table by Bonadonna G et al (Bonadonna G et al., 
1975). On subsequent studies, dacarbazine was administered on days 1 and 15 rather than on days 1-5 
(Canellos GP et al., 1992)  
cDerived from Diehl V et al. 2003 
dMaximum dose 2 mg. 
eFilgrastrim is given subcutaneously starting on day 8 and continuing until WBC ≥13,000/mm3on 3 
consecutive days. The dose is 300 mcg/day for patients with body weight <75 kg and 400 mcg/day for 
those ≥75 kg 
fDerived from Bartlett NL et al. 1995 
gVinblastine dose reduced to 4mg/m2 and vincristine dose to 1mg/m2 during cycle 3 for patients 50 
years of age or older 
hPrednisone is started on day 1 and continued every other day. It is tapered by 10 mg/dose every other 
day starting on day 14 of the third cycle 
Table 6. Common Chemotherapy Regimens Used for the Treatment of HL in Europe and USA. 
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Trial/Study Group Treatment Protocols 
No. of 
Patients 
Median 
Follow-up 
Treatment 
Outcomes 
Engert A et al. (2007) 
GHSG HD7 
A: RT alone (30 Gy EF-RT or 
40 Gy IF-RT) 
311 87 months 
7-yr FFTF, 67%; 
7-yr OS: 92% 
 
B: 2 ABVD + RT (30 Gy EF-
RT or 40 Gy IF-RT) 
316  
7-yr FFTF: 88%; 
7-yr OS: 94% 
Engert A et al. (2010) 
GHSG HD10, 1998–
2003 
A: 2 ABVD + IF-RT (30 Gy) 295 
91 months 
for OS and 
79 months 
for FFTF 
8-yr FFTF: 85.5 
8-yr OS: 93.6 
 
B: 2 ABVD + IF-RT (20 Gy) 299  
8-yr FFTF: 85.9 
8-yr OS: 95.1 
 
C: 4 ABVD + IF-RT (30 Gy) 298  
8-yr FFTF: 87.2 
8-yr OS: 94.4 
 
D: 4 ABVD + IF-RT (20 Gy) 298  
8-yr FFTF: 89.9 
8-yr OS: 94.7 
Advani RH et al. (2010) 
Stanforda 
A: Stanford V for 8 wk + IF-
RT (mostly 30 Gy, but some 
with 20 Gy) 
46 
(favorable 
factors 
GHSG) 
8.5 years 
10-yr FFP: 100% 
10-yr OS: 97% 
Press OW et al. (2001) 
SWOG 9133/CALGB 
9391 
A: 3 (doxorubicin + 
vinblastine) + STLI (S) (36–40 
Gy) 
165 3.3 years 
3-yr FFS:  94% 
3-yr OS: 98% 
 
B: STLI (S) (36–40 Gy) 161  
3-yr FFS: 81% 
3-yr OS: 96% 
Ferme C et al. (2007) 
EORTC/GELA H8F 
A: 3 MOPP/ABV + IF-RT (36 
Gy) 
270 92 months 
10-yr EFS: 93% 
10-yr OS 97% 
 
B: STLI (S) 272  
10-yr EFS 68%; 
10-yr OS 92% 
Horning SJ et al. (1999) 
Stanforda 
Stanford V for 8 wk + 
modified IF-RT (30 Gy) 
65 16 months 
3-yr FFP: 94.6% 
3-yr OS: 96.6% 
Noordijik EM et al. 
(2006) 
EORTC/GELA H7F 
A: 6 EBVP + IF-RT (36 GY) 164 9 years 
10-yr EFS: 88%; 
10-yr OS: 92% 
 
B: EF-RT 165  
10 yr FFTF: 78%; 
10 yr OS: 92% 
Meyer RM et al. (2005) 
NCIC-CTG/ECOG 
A: EF-RT alone 64 4.2 years 
5-yr EFS: 88% 
5-yr OS: 100% 
 
B: 4-6 cycles of ABVD alone 59  
5-yr EFS: 87% 
5-yr OS: 97% 
Eghbali H et al. (2005) 
EORTC-GELA H9-F 
A: 6 EBVP + IF-RT (36 Gy) 239 51 months 
4-yr EFS: 88% 
4-yr OS: 99% 
 
B: 6 EBVP + IF-RT (20 Gy) 209  
4-yr EFS: 85% 
4-yr OS: 100% 
 
C: 6 EBVP alone 130  
4-yr EFS: 69% 
4-yr OS: 98% 
Wirth A et al. (2011) 
ALLG/TTROGa 
3 ABVD followed by 30 Gy 
IF-RT 
?75 5.9 years 5-yr FFP: 97% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
dacarbazine; ALLG/TTROG, Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation 
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Oncology Group; AV, doxorubicin and vinblastine; AVD, doxorubicin, vinblastine, dacarbazine; 
CALGB, Cancer and Leukemia Group B; EF-RT, extended-field radiotherapy; EBVP regimen, 
epirubicin, bleomycin, vinblastine, and prednisone; ECOG, Eastern Cooperative Oncology Group; EFS, 
event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FFP, 
freedom from progression; FFS, failure-free survival; FFTF, freedom from treatment failure; GELA, 
Groupe d'Etude des Lymphomes de l'Adulte; GHSG, German Hodgkin Study Group; IF-RT, involved-
field radiation therapy; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; OS, overall 
survival; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; RFS, relapse-free 
survival; RT, radiotherapy; Stanford V, mechlorethamine, doxorubicin, vinblastine, prednisone, 
vincristine, bleomycin, VP-16; STLI (S), subtotal nodal irradiation (splenic irradiation); SWOG, 
Southwest Oncology Group; VAPEC-B, doxorubicin, cyclophosphamide, etoposide, vincristine, 
bleomycin, prednisone; yr, year. 
aUsed GHSG definition for early stage favorable HL 
Table 7. Selected Trials in Favorable Early Stage HL Derived from Major Study Groups. 
comparable outcomes to more intense regimens with FFP of 96% and OS of 98% after a 
median follow-up of 5.7 years. 
Furthermore, one of the recent “practice changing” important studies, the GHSG HD 10 
trial by Engert A et al (Engert, Plutschow, Eich, et al, 2010), randomized 1370 patients (age 
range, 16 to 75) with early stage favorable HL in a 4 arm study into 2 or 4 cycles of ABVD 
followed by 20 or 30 Gy IF-RT. Favorable disease included patients with no bulky disease, 
no extranodal extension, and without elevated ESR (see Table 4 for definitions of risk 
groups). With a median follow-up of 79-91 months, there were no significant differences 
in FFTF and OS in the 4 arms with FFTF rates in the range of 85.5% to 89.9% and OS  
rates in the range of 93.6% to 95.1% (Table 7). Furthermore, patients who received only  
two cycles of ABVD and low dose of radiation have less adverse events and acute toxic  
effects. 
The HD 13 randomized trial is trying to address the question, in order to decrease toxicity 
from ABVD, whether the number of drugs can be reduced. Patients in this study are 
randomly assigned to one of the 4 arms: ABVD, ABV, AVD, or AV chemotherapy followed 
by 30 Gy of IF-RT. An interim safety analysis in 2006 showed increased failure rates in the 
ABV and AV arms, hence those arms were closed. Until further evidence, dacarbazine 
should be considered an integral part of the ABVD regimen in early stage favorable HL. 
Future analyses of the HD 13 study would hopefully answer the question whether ABVD 
and AVD are equivalent or not (Borchmann & Engert, 2010). 
4.3.3 Early stage unfavorable cHL 
The standard of care based on multiple randomized studies remains the combined modality 
treatment with chemotherapy and RT, as for the early stage favorable HL. However, there 
has been a trend towards more intense therapy than early favorable stage HL with some 
investigators suggesting therapy approaches similar to those adopted for advanced HL. 
However, giving the high cure rates and prolonged CR rates, there have been many 
randomized studies trying to address the need for less intense chemotherapy and/or RT in 
order to decrease long term toxicity from RT and maintain the best response rates. Table 8 
summarizes some of the major studies addressing the therapeutic approaches for early stage 
unfavorable HL with the associated response rates. 
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4.3.3.1 Brief historical background for chemotherapy use in early stage unfavorable cHL 
Various chemotherapeutic regimens have been investigated in the combined modality 
treatment for early stage unfavorable HL since early 1980’s. However, studies didn’t 
identify significant survival advantages among different modalities. Based on data 
derived from major studies in advanced HL, ABVD has been favored in most recent 
studies as first line therapy combined with RT in this population. ABVD has been favored 
for its superior outcomes and low late toxicity profile compared to other more intense 
regimens. Stanford V has been studied as well with some promising data and more 
recently ABVD has been compared to more intense regimens such as BEACOPP in early 
stage unfavorable HL. 
Earlier studies in unfavorable HL patients compared CMT with MOPP to ABVD and 
MOPP-like combinations. One of the earlier studies is the Milan study (Santoro, Viviani & 
Zucali, 1983) which randomized patients in a split fashion for 3 cycles of MOPP followed by 
subtotal nodal irradiation followed by another 3 cycles of MOPP versus same course but 
with ABVD rather than MOPP. No significant differences in FFP were noticed initially. 
However, the EORTC H6U trial (Cosset, Ferme, Noordijk, et al, 1996) showed a better 10-
year FFTF with ABVD compared to MOPP, though there was no significant survival 
advantage as in many other subsequent studies. 
In an attempt to improve efficacy and reduce toxicity, few studies were conducted with 
modified combinations such as reducing alkylating agents or total cumulative dosage of 
chemotherapy. However, inferior outcomes were noticed in the unfavorable early stage HL 
with these approaches (Table 8).  
One of such experiences was the Cancer and Leukemia Group B 9051 phase II study 
(Wasserman, Petroni, Millard, et al, 1999) which tested three cycles of etoposide, vinblastine, 
and doxorubicin (EVA) followed by subtotal lymphoid irradiation in 59 patients with CS I-
III disease and unfavorable features (bleomycin was eliminated). CR rate was about 66% 
with high relapse rate of 20%.  
In a more recent study (the EORTC H7U trial) conducted by the EORTC group (Noordijk, 
Carde, Dupouy, et al, 2006), 389 patients with unfavorable prognosis early stage HL were 
randomized to receive CMT with six cycles of epirubicin, bleomycin, vinblastine, and 
prednisone (EBVP) and IF-RT versus 6 cycles of mechlorethamine, vincristine, procarbazine, 
prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV hybrid) and IF-RT. The 
EBVP regimen, given one time per month (compared with two times per month for ABVD), 
was anticipated to be a less toxic regimen. However, the 10-year EFS rate was 88% in the 
MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS 
rates of 87% and 79%, respectively (P = .0175). Also, the failure-free survival rate at three 
years was significantly lower with EBVP (72 versus 88 percent) and further entry into the 
trial was discontinued. 
4.3.3.2 Popular chemotherapy regimens, number of cycles, and dose/field of radiation 
Recent studies, focused on the more popular regimens such as the ABVD, Stanford V, and 
BEACOPP, and as well on the number of cycles and dose/field of RT in order to enhance 
the outcomes and decrease toxicities (Table 8). 
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Trial/Study Group Treatment Protocols 
No. of 
Patients 
Median 
Follow-up 
Treatment 
Outcomes 
Cosset J et al. (1996) 
EORTC H6U 
A: 3 MOPP + mantle RT + 3 MOPP 165  
10-yr FFP: 68% 
10-yr OS: 87% 
  
B: 3 ABVD + mantle RT + 3 ABVD 151  
10-yr FFP: 90% 
10-yr OS: 87% 
Santoro A et al. 
(1983) 
Istituto Nazionale 
Tumori, Milan 
A: 3 MOPP + STLI/TLI + 3 MOPP 33  5-yr FFP: 66% 
  B: 3 ABVD + STLI/TLI + 3 ABVD 36  5-yr FFP: 72% 
Pavlovsky S et al. 
(1997) 
GATLA 
A: 3 CVPP + IF-RT (30 Gy) + 3 
CVPP 
92  
5-yr EFS: 85% 
5-yr OS: 95% 
  B. 3 AOPE + IF-RT (30 Gy) + 3 
AOPE 
84  
5-yr EFS: 66% 
5-yr OS: 87% 
Noordijik EM et al. 
(2006) 
EORTC H7U 
A: 6 EBVP II + IF-RT (36 GY) 194 9 years 
10-yr EFS: 68%; 
10-yr OS: 79% 
  
B: 6 MOPP/ABV + IF-RT 195  
5-yr EFS, 88%; 
5-yr OS 87% 
Meyer RM et al. 
(2005) 
NCIC-CTG/ECOG 
A: 2 ABVD followed by EF-RT 139 4.2 years 
5-yr EFS: 88% 
5-yr OS: 92% 
 
B: 4-6 ABVD alone 137  
5-yr EFS: 85% 
5-yr OS: 95% 
Eich HT et al. 
(2010) 
GHSG HD11 
A: 4 ABVD + IF-RT (30 Gy) 356 6.8 years 
5-yr FFTF: 85.3% 
5-yr OS: 94.3% 
 
  
B: 4 ABVD + IF-RT (20 Gy) 347  
5-yr FFTF: 81.1% 
5-yr OS: 93.8% 
 
  
C: 4 baseline BEACOPP + IF-RT 
(30 Gy) 
341  
5-yr FFTF: 87% 
5-yr OS: 94.6% 
 
  
D: 4 baseline BEACOPP + IF-RT 
(20 Gy) 
351  
5-yr FFTF: 86.8% 
5-yr OS: 95.1% 
 
Advani RH et al. 
(2010) 
Stanforda 
A: Stanford V for 8 wk + IF-RT (20 
or mostly 30 Gy) 
55 8.5 years 
10-yr FFP: 89% 
10-yr OS: 96% 
Wirth A et al. 
(2011) 
ALLG/TTROGa 
4 ABVD followed by 30 Gy IF-RT 
for: 
A. Stage IA-IIA with any risk 
factor 
B. Stage IB-IIB: 
 
 
A. 47 
 
B. ?26 
5.9 years 
 
 
 
A. 5-yr FFP: 89% 
 
B. 5-yr FFP: 73% 
 
Zittoun R et al. 
(1985) 
A: 3 MOPP + IF-RT (40 Gy) + 3 
MOPP 
82  
6-yr DFS: 87% 
6-yr OS: 92% 
www.intechopen.com
 
Hodgkin's Lymphoma 
 
128 
Trial/Study Group Treatment Protocols 
No. of 
Patients 
Median 
Follow-up 
Treatment 
Outcomes 
French Cooperation 
  B: 3 MOPP + EF-RT (40 Gy) + 3 
MOPP 
91  
6-yr DFS: 93% 
6-yr OS: 91% 
Bonadonna G e al. 
(2004) 
Istituto Nazionale 
Tumori, Milanb 
A: 4 ABVD + STLI 66 116 months 
12 yr FFP: 93% 
12-yr OS: 96% 
  
B: 4 ABVD + IF-RT 70  
12-yr FFP: 94% 
12-yr OS: 94% 
Ferme C et al. 
(2007) 
EORTC/GELA 
H8U 
A: 6 MOPP/ABV + IF-RT (36 Gy) 336 92 months 
10-yr EFS: 82% 
10-OS: 88% 
  
B: 4 MOPP/ABV + IF-RT (36 Gy) 333  
10-yr EFS: 80% 
10-yr OS: 85% 
  
C: 4 MOPP/ABV + STLI 327  
10-yr EFS: 80% 
10-yr OS: 84% 
Engert A et al. 
(2003) 
GHSG HD8 
A: 4 COPP/ABVD + 30 Gy EF-RT 
(+ 10 Gy to bulky disease) 
532 54 months 
5-yr FFTF: 85.8% 
5-yr OS: 90.8% 
  A: 4 COPP/ABVD + 30 Gy IF-RT 
(+ 10 Gy to bulky disease) 
532  
5-yr FFTF: 84.2% 
5-yr OS: 92.4% 
ABV, doxorubicin (Adriamycin), bleomycin, vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, 
dacarbazine; ALLG/TTROG, Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation 
Oncology Group; AOPE, doxorubicin, vincristine, prednisone, etoposide; BEACOPP, bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; COPP, 
cyclophosphamide, vincristine, procarbazine, prednisone; CVPP, cyclophosphamide, vinblastine, 
procarbazine, prednisone; DFS, disease-free survival; EBVP, epirubicin, bleomycin, vinblastine, 
prednisone; ECOG, Eastern Cooperative Oncology Group; EF-RT, extended-field radiotherapy; EFS, 
event-free survival; EORTC, European Organization for Research and Treatment of Cancer; FFP, 
freedom from progression; FFTF, freedom from treatment failure; GATLA, Grupo Argentino de 
Tratamiento de la Leucemia Aguda; GELA, Groupe d'Etude des Lymphomes de l'Adulte; GHSG, 
German Hodgkin Study Group; IF-RT, involved-field irradiation; MOPP, mechlorethamine, vincristine, 
procarbazine, prednisone; NCIC-CTG, National Cancer Institute of Canada Clinical Trials Group; OS, 
overall survival; Stanford V, mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, 
bleomycin, VP-16; RT, radiation therapy; STLI, subtotal nodal irradiation; TLI, total lymphoid 
irradiation.  
aUsed GHSG definitions for favorable and unfavorable early stage HL 
bIncluded unfavorable stage I and all clinical stage II patients 
Table 8. Selected Trials in Unfavorable Early Stage HL Derived from Major Study Groups. 
Trying to address the number of cycles and/or radiation field, Ferme C, et al. randomized 
996 patients with early unfavorable HL in the GELA H8U trial into one of the following 
three arms: six cycles of the hybrid MOPP/ABV regimen plus IF-RT versus four cycles plus 
IF-RT versus 4 cycles plus subtotal nodal irradiation (STNI). All arms had similar 5-year EFS 
and 10-year OS rates (Ferme, Eghbali, Meerwaldt, et al, 2007). Hence, 4 cycles of 
chemotherapy followed by IF-RT was proposed as standard treatment for early stage 
unfavorable HL. EF-RT versus IF-RT has been addressed as well by the large HD8 
randomized trial from the German Hodgkin's Lymphoma Study Group (Engert, Schiller, 
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Josting, et al, 2003), where 1204 patients were randomly assigned to receive four cycles of 
COPP/ABVD followed by either IF-RT or EF-RT. At 5-years of follow-up, there was no 
significant difference in FFTF and OS between the 2 groups, but increased acute toxicity 
with the EF-RT group (leukopenia, thrombocytopenia, and GI toxicities). 
ABVD and BEACOPP have been compared head to head in early stage unfavorable HL. In 
the EORTC/GELA H9U study (Noordijk EM, 2005) patients were randomly assigned to 6 
cycles of ABVD or 4 cycles of ABVD or 4 cycles of baseline BEACOPP, all followed by 30 Gy 
IF-RT. At an interim analysis with a median follow-up of 4 years, no EFS and OS differences 
were noted, but increased toxicity with baseline BEACOPP. More recently, the final analysis 
of the GHSG HD11 trial (Eich, Diehl, Gorgen, et al, 2010) has been published with similar 
results to the H9U study, but with more information about the RT dosage. In this 4-arm 
study, 1395 patients with early stage unfavorable HL were randomized to either 4 cycles of 
ABVD or 4 cycles of baseline BEACOPP. Patients in each group of chemotherapy were then 
randomized to either 20 or 30 Gy IF-RT. At a median follow-up of 7.5 years, the OS was 
similar in all 4 arms. FFTF and PFS were similar as well between the 2 chemotherapy arms 
with the 30 Gy IF-RT. Baseline BEACOPP arm with 20 Gy IF-RT showed superior FFTF 
compared to ABVD followed by same RT. However, treatment-related toxicity was more 
frequently observed in the baseline BEACOPP arm and hence the BEACOPP is not adopted 
as new standard of care. 
More recently, Wirth and colleagues (Wirth, Grigg, Wolf, et al, 2011) reported the results of 
the Australian Leukemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group 
which tested combined modality treatment in stages I-II HL with IF-RT, with the number of 
cycles of ABVD determined by risk group (according to GHSG). 150 patients were classified 
into three groups as follows: group 1 with no risk factors who received 3 cycles of ABVD 
and IF-RT, group 2 with stages IA-IIA disease and any of the risk factors and group 3 
included patients with stage IB-IIB; groups 2 and 3 received the same therapy with 4 cycles 
of ABVD and IF-RT. With a median follow-up of 5.9 years, the 5-year FFP and OS were 
comparable to those in the HD10 and HD11 trials for groups 1 and 2, but not group 3 which 
showed lower 5-year FFP and OS of 73% and 85%, respectively. The lower rates in group 3 
may be explained by the inclusion of stage IIBX disease (44% of patients) in this study (those 
were excluded from HD10 and HD11 studies). 
As with ABVD and BEACOPP, clinical studies has shown promising response rates with the 
Stanford V regimen. Advani RH, et al (Advani, Hoppe, Baer, et al, 2009) updated recently 
the initial results of the G4 study published by Horning SJ et al (Horning SJ, 2004). Among 
the 87 patients with non-bulky stage IA-IIA HL, 47 patients had unfavorable risk factors 
(according to GHSG criteria). At a median follow-up of 9 years, the FFP and OS rates for the 
whole group were 94% and 96%, respectively. However, FFP was 100% for favorable disease 
patients compared to 89% of those with unfavorable factors, but with no significant OS 
differences. Hence, Stanford V (8 weeks; 2 cycles) and 30 Gy IF-RT is considered safe and 
highly effective in this group of patients.  
Few other studies confirmed as well that combined modality with Stanford V regimen is 
highly effective for locally extensive and advanced HL with low toxicity profile. More 
recently, the MSKCC study (Edwards-Bennett, Jacks, Moskowitz, et al, 2010) tested 126 
patients with either locally extensive or advanced disease with 12-week Stanford V 
chemotherapy regimen followed by 36 Gy IF-RT to bulky sites and/or macroscopic splenic 
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disease. The 5-and 7-year OS rates were 90% and 88%, respectively. On the other hand, at 
least 3 randomized trials were conducted comparing combined modality treatment with 
Stanford V versus ABVD. The final results confirm that ABVD should stay the standard 
therapy, but offers Stanford V as an acceptable and effective alternative (NCCN, v2.2011). 
4.3.4 Chemotherapy alone 
Giving the high cure rates and long term survivors of early stage HL with combined 
modality therapy, but with continued increased risk of long term complications from RT 
such as premature heart disease, lung toxicity, and secondary malignancies, many 
investigators have initiated randomized studies trying to omit RT in such good risk patients. 
Data from few randomized studies and as well few other single arm studies will be 
discussed briefly (these were summarized by a recent review by Straus DJ, 2011). 
One of the earliest randomized studies is the prospective trial by Pavlovsky S, et al 
(Pavlovsky, Maschio, Santarelli, et al, 1988). A total of 104 patients with unfavorable clinical 
stages I-II HL were randomized for chemotherapy alone with 6 cycles of CVPP 
(cyclophosphamide, vincristine, procarbazine, and prednisone) versus 6 cycles of CVPP 
sandwiched with 30 Gy dose of IFRT. Combined modality treatment had higher rates of 
disease-free survival (75% vs. 34%) and a trend toward higher OS rates (84% vs. 66%). 
Another prospective study was conducted by the Memorial Sloan Kettering Cancer Center 
(Straus, Portlock, Qin, et al, 2004) which randomized 152 patients with non-bulky stages I-II 
and stage IIIA disease to 6 cycles of ABVD with or without RT. There were no significant 
differences, but increased tendency for inferior outcomes in CR rates (87% vs. 91%), FFP 
rates (81 vs. 86%), and OS at 60 months (90% vs. 97%) for ABVD alone compared to the 
combined modality arm.  
A phase II trial by the NCIC and ECOG study group (Meyer, Gospodarowicz, Connors, et al, 
2005) randomized 399 patients with non-bulky early stage IA-IIB HL to 4-6 cycles of ABVD 
alone (favorable or unfavorable) vs. RT based therapy (STLI alone if favorable HL and 
ABVD followed by STLI if unfavorable). An interim analysis after median follow-up of 4.2 
years revealed better outcomes (FFP and EFS) in the RT alone plus combined modality 
therapy arms compared to the chemotherapy alone arm, but no survival benefit. In a subset 
analysis of patients with unfavorable prognostic factors, FFP was superior for those treated 
with the combined modality compared to chemotherapy alone (95% vs. 88%), but with no 
survival differences.  
The fourth 3-arm randomized study is the EORTC-GELA H9-F (Eghbali, Raemaekers & 
Carde, 2005) which randomized early stage favorable HL patients (total of 783 patients) to 
chemotherapy alone with epirubicin, bleomycin, vinblastine, and prednisone (EBVP) versus 
EBVP followed by 20 Gy of IF-RT versus EBVP followed by 36 Gy IF-RT. EBVP has an 
inferior outcome compared to the combined modality with both the 20 Gy and 36 Gy IF-RT 
with 4-year EFS rates of 69%, 85%, and 88%, respectively. The EBVP alone arm was then 
discontinued though there was no survival differences. 
Of the retrospective analyses, Canellos GP et al (Canellos, Abramson, Fisher, et al, 2010) 
reported a PFS and OS of 92% and 100%, respectively, in a series of 75 patients with early 
stages IA-IIA and stage IIB disease (median follow-up was 52 months). Another 
nonrandomized study from Spain (Rueda Dominguez, Marquez, Guma, et al, 2004) included 
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unselected 80 patients with early stage HL treated with 6 cycles of ABVD. The progression-
free and overall survival at 7 years reported in 65 patients without B symptoms or 
mediastinal bulky disease were 88% and 97%, respectively. 
More recently, a systematic review with meta-analysis of randomized controlled trials 
comparing chemotherapy alone with CMT in patients with early stage HL. Randomized 
studies comparing chemotherapy alone to the same chemotherapy regimen plus RT were 
only included. A total of 1245 patients were included. Authors concluded that adding RT to 
chemotherapy improves tumor control and OS in patients with early stage HL (Herbst, 
Rehan, Skoetz, et al, 2011). 
Until further randomized trials are published, there will be no consensus to adopt 
chemotherapy alone as front line therapy for early stage HL. Enrollment in randomized 
clinical trials should be highly recommended. Currently, there are few ongoing randomized 
studies trying to answer that question. Armitage (Armitage, 2010) summarized four major 
randomized clinical trials which are incorporating interim PET scans to guide further 
therapy with or without IF-RT.  
Based on available data and until further studies show convincing evidence for the opposite, 
we think combined modality treatment with chemotherapy and RT should remain the 
standard of care for early stage HL. Exceptions can be made for individual cases with either 
chemotherapy alone or RT alone. Of significance, and as noted by Armitage (Armitage, 
2010), it appears that the actual choice of treatment modality is greatly affected by a 
physician’s comfort with a particular treatment and by cumulative clinical experience- not 
just by data published in the literature. 
4.4 Treatment of early stage NLPHL 
4.4.1 Introduction 
As discussed above, NLPHL is a rare subtype of HL with distinctive morphologic and 
immunophenotypic features compared to cHL. NLPHL accounts for 5% of HL cases with 
around 500 new diagnoses in US annually. Many retrospective analyses showed different 
natural history and more indolent course than cHL. Given the rarity of NLPHL, there are no 
randomized studies to establish standard of care for management of NLPHL. It has been 
managed historically similarly to cHL, however distinctive features are more recognized 
currently with some changes in the approach of management. 
4.4.2 Presentation and prognosis 
Generally, NLPHL is characterized by early presentation (stages I-II), indolent course with 
no constitutional symptoms, favorable prognosis, and occasional late relapses. The 
extremely favorable prognosis on some cases is reflected by data which showed that 
patients with stage IA may be treated with LN excision followed by a “watch and wait” 
approach or with IFRT alone (Diehl, Sextro, Franklin, et al, 1999; Nogova, Reineke, Eich, et al, 
2005; Schlembach, Wilder, Jones, et al, 2002; Wilder, Schlembach, Jones, et al, 2002; Wirth, 
Yuen, Barton, et al, 2005) and that some patients with Stages IIIA-IVA may benefit as well 
from the “watch and wait” approach until they become symptomatic without jeopadarizing 
treatment outcomes.  
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The largest analysis to describe patients with NLPHL and identify certain prognostic factors 
is the recent report by Nogova , et al (Nogova, Reineke, Brillant, et al, 2008) who reviewed 
all NLPHL patients registered in the GHSG database, comparing patient characteristics and 
treatment outcome with cHL patients. A total of 394 patients with NLPHL were identified 
with 63 % having early stage favorable, 16 % has early stage unfavorable, and 21% has 
advanced stage. At a median follow-up of 50 months, FFTF (88% vs 82%) and OS (96% vs 
92%) were found better with NLPHL compared to cHL, respectively. Among patients with 
NLPHL, FFTF were superior in patients with early favorable HL compared to those with 
early unfavorable HL and advanced HL (93% vs 87% vs 77%, respectively). The following 
factors were found negative prognostic factors: age (≥ 45), advanced stage, hemoglobin 
<10.5 g/dl, and lymphopenia. In another, but smaller series, Diehl V et al (Diehl, Sextro, 
Franklin, et al, 1999) reported similar favorable outcomes for early stage disease NLPHL 
compared to more advanced stages. 
4.4.3 Treatment options 
IF-RT or regional RT alone has been accepted by most investigators in Europe and US as a 
valid choice in the setting of non-bulky stage IA-IIA NLPHL, and is adopted as first line 
therapy by the NCCN guidelines. This is based on many retrospective analyses which 
showed excellent long term outcomes and no added benefit with combined modality 
therapy as for cHL. The Australasian Radiation Oncology Lymphoma Group (Wirth, Yuen, 
Barton, et al, 2005) described the long term outcomes of 202 patients with stage I-II NLPHL 
treated with RT alone. At a median follow-up of 15 years, the FFP and OS rates for the 
whole group were 82 % and 83 %, respectively. Various RT fields were used in this 
population with a median RT dose of 36 Gy. Another small series of 36 patients reported 
treatment outcomes with RT alone for non-bulky stage IA-IIA NLPHL (Schlembach, Wilder, 
Jones, et al, 2002). In this small series, 20 patients with stage IA received either IF-RT or EF-
RT alone. At a median follow up of 8.8 years, the 5-year relapse-free and OS rates were 95% 
and 100%, respectively.  
Treatment outcomes for early stage NLPHL with RT with or without chemotherapy have 
been reported in few other retrospective analyses. Chen RC et al (Chen, Chin, Ng, et al, 2010) 
reported recently the outcomes from 113 patients with stage I-II NLPHL treated with RT 
alone (93 patients), combined modality (13 patients), or chemotherapy alone (7 patients). 
Among the 106 patients treated with RT, 25 received limited-field, 35 regional-field, and 46 
received EF-RT. At a median follow-up of 136 months, 10-year PFS rates were 85% (stage I) 
and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II 
respectively. PFS and OS did not differ among patients who received limited-field, regional-
field, or extended-field RT. In contrast, six of seven patients who received chemotherapy 
alone developed early disease progression. In a multivariate analysis, extent of RT was not 
significantly associated with PFS. Addition of chemotherapy to RT didn’t improve the 
outcomes as well. 
Nogova L et al (Nogova, Reineke, Eich, et al, 2005) reported a retrospective analysis, from 
the GHSG, which included 131 patients with stage IA NLPHL treated with either IF-RT 
alone (45 patients), ER-FT alone (45 patients), or the RT combined with two to four cycles of 
ABVD chemotherapy (41 patients). At a median follow-up of 78 months for EF-RT, 17 
months for the IF-RT, and 40 months for the combined modality, the estimated 24-month 
FFTF rates were 100, 92, and 97 percent, respectively for the three treatment groups. In 
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another small series (48 patients), but with longer median follow-up (9.3 years), the M.D 
Anderson study (Wilder, Schlembach, Jones, et al, 2002) showed no difference in treatment 
outcomes for early stage NLPHL with RT alone (37 patients) compared to combined 
modality (11 patients). 
Based on current data and until future convincing evidence is available, we think IF-RT alone 
is the preferred first line treatment modality for early stage favorable NLPHL. There is a 
general agreement for now by most investigators to treat patients with early unfavorable or 
advanced-stage LPHL according to the treatment protocols for cHL. However, with more data 
investigating the role of the monoclonal anti-CD 20 antibody (Rituximab) in patients with 
NLPHL, many investigators recommend incorporating rituximab alone or combined with 
other treatment modalities for unfavorable early stage, advanced stage, and relapsed NLPHL.  
5. Special cases 
5.1 Treatment of elderly patients with HL 
5.1.1 Introduction 
HL is a disease of relatively young patients; however, about 15-30% of patients with HL 
are older than 60 years according to few population-based studies. Elderly patients are 
mostly defined as those above ages 60-65 years. Unfortunately, the reported rates of 
elderly HL patients enrolled in large randomized studies is much lower than its 
prevalence (<5% to 10%) (Evens, Hutchings & Diehl, 2008; Klimm, Diehl & Engert, 2007). 
There is paucity of randomized studies that targeted the elderly HL population alone. 
However, many retrospective analyses derived from large studies have addressed the 
elderly population.  
5.1.2 Presentation and prognosis 
Elderly patients tend to present with increased frequency of mixed cellularity histologic 
subtype, advanced disease, B symptoms, and Epstein-Barr virus-positive disease. Overall, 
patients older than 60 years tend to have poorer outcomes than the younger population as 
reported by most series. Poor outcomes may be attributed to various factors including 
multiple co-morbidities, poor performance and/or mental status, inability to tolerate 
aggressive therapy, and death due to causes other than HL, among other factors as 
discussed below (Evens, Hutchings & Diehl, 2008; Klimm, Diehl & Engert, 2007). 
Kim HK et al (Kim, Silver, Li, et al, 2003) reported treatment outcomes of 86 elderly patients 
(60-93 years) among which 52 patients had early stage disease (stages IA-IIA) and 34 
patients had advanced disease (stages IIB-IV). At a median follow-up of 75 months, the 10-
year FFTF and OS rates for all patients were 62% and 30%, respectively. The 10-year FFTF 
and OS for early stage HL were 71% and 31% and for advanced stage HL were 49% and 
26%, respectively. In this study, the recurrence of HL was found to have a significant 
negative impact on survival. In a more recent report by Engert A et al (Engert, Ballova, 
Haverkamp, et al, 2005), a comprehensive retrospective analysis from the GHSG data base 
was performed and yielded poorer outcomes for elderly patients. From 4251 patients, 372 
(8.8%) were 60 years or older. The 5-year OS (65% vs. 90%) and FFTF (60% vs. 80%) rates 
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were significantly lower than those in younger patients. It was noticed in this study that the 
acute toxicity rate was higher in the elderly and that fewer elderly patients received the 
intended full dose chemotherapy. Hence, the authors concluded that the overall poorer 
outcome of elderly HL patients is attributed to the higher mortality during treatment and 
the lower dose-intensity therapy received. Of notice in this study, and as have been noticed 
with few other reports, adequately staged elderly patients receiving appropriate doses of 
therapy can achieve responses comparable to those of younger patients. However, older 
patients in general have a less favorable outcome which may be attributed to treatment-
related deaths, shorter survival after relapse, death due to other causes, and others as 
mentioned above. Few other reports over the past 3-4 decades have been published with 
similar outcomes as above. 
5.1.3 Treatment options 
To date and until proven otherwise, there is an agreement among different investigators to 
treat the best fit elderly patients according to the management guidelines for the younger 
population, early stage HL with CMT and advanced stage disease with chemotherapy with 
or without RT as indicated. If chemotherapy is indicated, the widely used ABVD regimen 
would probably be the preferred regimen over the less commonly used and/or more 
intense-toxic regimens such as Stanford V and BEACOPP. 
Over the past 10 years, attempts are being made to define the best therapeutic approach for 
elderly patients. Adjusting the chemotherapy and/or RT protocols to maintain high efficacy, 
but decrease the toxicity have been tried.  
For patients with early stage unfavorable HL, Klimm et al. (Klimm, Eich, Haverkamp, et 
al, 2007) reported in 2007 the GHSC experience for the elderly early stage HL after CMT 
with 4 cycles of chemotherapy (COPP/ABVD) followed by EF-RT vs. IF-RT. From 1204 
patients enrolled in the GHSG HD8 study, 89 patients were 60 years or older. Acute 
toxicity from RT was more pronounced in elderly patients receiving EF-RT compared to 
IF-RT. FFTF and OS rates were significantly lower in the elderly patients compared to 
younger population. However, more importantly, this study reported that elderly patients 
had poorer outcome when treated with EF-RT compared to IF-RT in terms of FFTF (58% 
vs. 70%) and OS (59% vs. 81%). 
In regards of best chemotherapy regimen, data suggest that best outcomes in the elderly HL 
patients were received with adriamycin-based therapy. Weekes et al. (Weekes, Vose, Lynch, 
et al, 2002) reported that patients received anthracycline-containing regimen (ChlVPP/ABV) 
survived twice as long as patients given ChlVPP alone. Ballova et al. (Ballova, Ruffer, 
Haverkamp, et al, 2005), on the other hand in the HD9 elderly study, tried more intense 
regimen with baseline BEACOPP compared to COPP-ABVD in patients (>60 years) with 
advanced stage HL. Although there was better tumor control in the BEACOPP arm, that 
didn’t translate into better outcome because of the higher toxicity.  
More recently, and in an attempt to maintain dose intensity and avoid excessive toxicity, 
CHOP-21 regimen which is traditionally used for NHL has been studied as front line 
therapy for elderly HL patients with promising results (Kolstad, Nome, Delabie, et al, 2007). 
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There have been few other regimens tested in single arm phase II studies and others are being 
under investigation with various successes to date. Examples of such regimens include 
vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone and bleomycin 
(VEPEMB) (Levis, Anselmo, Ambrosetti, et al, 2004), vincristine, doxorubicin, bleomycin, 
etoposide and prednisone (ODBEP) (Macpherson, Klasa, Gascoyne, et al, 2002), prednisone, 
vinblastine, doxorubicin and gemcitabine (PVAG) (Boll, Bredenfeld, Gorgen, et al, 2011), and 
bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbacine and prednisone 
(BACOPP) (Halbsguth, Nogova, Mueller, et al, 2010). However, randomized studies are highly 
recommended in this elderly heterogenous population in order to adopt any of the new 
regimens as standard of care compared to traditional regimens such as ABVD. 
We do think that using a comprehensive geriatric assessment (CGA) model for elderly HL 
patients, addressing comorbidity and functional status prior to initiation of therapy, may 
guide medical providers in their decision for the intense of therapy which usually predicts 
treatment outcomes. A similar approach has been studied in elderly patients with diffuse 
large cell lymphoma (Tucci A et al, 2009) where GCA was found to be an efficient method to 
identify elderly patients who may benefit from a curative approach with aggressive therapy 
(well fit patients) compared to unfit patients who have poor outcomes. Until more data is 
available, treatment of well fit elderly patients should follow same guidelines as for younger 
population given the potentially high cure rate of HL even in advanced disease status as 
compared to poor outcomes with other types of cancers. 
5.2 Treatment of HL during pregnancy 
5.2.1 Epidemiology and prognosis 
As the HL high incidence rates coincides with the female reproductive age, it is not 
surprising to mention that it is considered the fourth most common cancer during 
pregnancy (Sadural & Smith, 1995). However, as the overall incidence/prevalence of HL 
is low compared to other cancers the association between pregnancy and HL is low as 
well with only few small series describing the clinical presentation and treatment 
outcomes in this population. Fortunately, most reports showed that pregnancy doesn’t 
have a negative impact on the course of HL with long term treatment outcomes 
comparable to those who were treated while non-pregnant (Gelb, van de Rijn, Warnke, et 
al, 1996). The challenge in managing those cases is attributed to the increased risk on the 
fetus with the different diagnostic and/or therapeutic interventions. Adverse teratogenic 
effects from chemotherapy and/or RT depend mainly on the level of fetal maturation. The 
highest teratogenic effects with increased risk of fetal malformation and death are noticed 
in the first trimester. In the second and third trimester, complications from therapy are 
more subtle with adverse effects such as intrauterine growth retardation, impaired 
functional or mental development, microcephaly, and low birth weight, among others 
(Fisher & Hancock, 1996). 
5.2.2 Presentation and staging 
Clinical presentation of HL during pregnancy is generally similar to non-pregnant patients. 
Staging workup approach is similar as well; however, to avoid fetus exposure to RT, CT 
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scans should be avoided if possible. Instead, CXR and abdominal US and/or MRI may be 
used safely to complete staging (Nicklas & Baker, 2000). 
5.2.3 Treatment options 
There are no consensus guidelines to date that address standard of care. However, based on 
the available scattered reports there is an agreement to manage pregnant patients 
conservatively if possible until fetal maturation or delivery. Some authors suggested that in 
specialized cases (such as those with limited stage IA-IIA in their late second and third 
trimester), treatment may be deferred until mature fetal development and delivery, but 
patients should be followed then very closely for any signs of progression and proceed with 
delivery and/or therapy as indicated (Gelb, van de Rijn, Warnke, et al, 1996; Jacobs, 
Donaldson, Rosenberg, et al, 1981). 
Patients who present with HL during the first trimester, in particular those with advanced 
disease, may be offered therapeutic abortion given the high risk of teratogenic effects 
associated with therapy. Data suggest that chemotherapy increases risk of fetal 
malformations to around 15% during the first trimester, with the greatest risk associated 
with the alkylatng and antimetabolite drugs, as opposed to the lowest risk with 
vinblastine (Doll, Ringenberg & Yarbro, 1989; Yahalom, 1990). Of notice, Doll DC et al. 
reported as well that there was low risk of fetal malformation in the second and third 
trimesters. In contrast, RT has been used more safely during pregnancy even in the first 
trimester. Yahalom J (Yahalom, 1990), in a series of 23 patients received 
supradiaphragmatic radiation therapy (five in the first trimester), reported no harm to the 
fetus. Based on these data and other similar reports, if treatment is indicated in the first 
trimester and can’t be delayed for the second trimester, RT (with maximized  
uterine shielding) may be considered the best choice for supradiaphragmatic disease  
(with a dose of less than 10 Gy). However, for patients with infradiaphragmatic  
disease and/or advanced disease chemotherapy may be indicated with vinbastine-based  
therapy. 
For second and third trimesters, treatment may be deferred until complete fetal 
development and safe delivery in specific asymptomatic localized stages. However, most 
patients would need treatment which may include RT alone (10 to 36 Gy in a mantle or IF-
RT fashion) for supradiaphragmatic disease (with maximized uterine shielding) vs. 
chemotherapy for infradiaphragmatic and/or advanced disease as for the first trimester; 
however, in the second and third trimesters the use of chemotherapy is much safer than in 
the first trimester (Barnicle, 1992; Doll, Ringenberg & Yarbro, 1989), but remote side effects 
on long term survivor babies remain of concern. 
6. Novel treatments for early stage HL 
Besides the increased use of the monoclonal anti-CD20 antibody (rituximab) in NLPHL, 
novel targeted therapy is rarely incorporated in the management of early stage HL. This is 
mainly because of the high cure rates achieved with traditional chemotherapy regimens. 
Novel therapies are being more studied in advanced and relapsed/progressive diseases and 
will be discussed separately.  
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7. Conclusion 
The treatment of early stage classical HL is mostly, today a combined modality with 
chemotherapy and involved field radiation. Decreasing the long-term side effects of the 
treatment is a goal. Decreasing the dosing of radiation and improving the radiation 
techniques, may demonstrate less complications in long-term follow-up. Incorporation of 
PET scan as a tool may select patients who will have higher risk for relapse. It is imperative 
to consider the acute and long-term side effects of the current therapeutic modalities in the 
treatment planning and future clinical trials. 
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